S. H. Tan - Natl Canc Ctr Singapore, Div Clin Trials & Epidemiol Sci, Singapore, Singapore

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 23 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Updated First-line Osimertinib in Asian patients with Advanced EGFR-mutated Lung Cancer

W. L. Tan,S. H. Tan, D. S. W. Tan, G. G. Y. Lai, M. -K. Ang, A. Jain, R. Kanesvaran, T. Rajasekaran, S. P. L. Saw, Y. L. Teh, J. Chan,Q. S. Ng,

JOURNAL OF THORACIC ONCOLOGYno. 11 (2023): S652-S653

引用0浏览0引用

192P ddPCR versus plasma NGS in detecting clearance of plasma EGFR mutations

P.L.S. Saw,G.S. Tan,A. Tan, G. Lai, W.C. Tan,E.H. Tan, M-K. Ang,D.W-T. Lim,R. Kanesvaran,Q.S. Ng, A. Jain, W.L. Tan,

Journal of Thoracic Oncology（2023）

引用1浏览0引用

P2.13-02 Dynamic Tracking of Bespoke Circulating Tumour DNA During Multi-Modality Therapy for Locally Advanced NSCLC (LA-NSCLC)

K.L.M. Chua,A. Tan,S. Saw, G. Lai, W.L. Tan, A. Jain, T. Rajasekaran, B. Chia,Y. Li, K.W. Fong, T.R. Siow,Q.S. Ng,

Journal of Thoracic Oncology（2022）

引用0浏览0引用

Real-World Data Of Osimertinib In Patients With Metastatic Egfrm Plus Nsclc Who Progressed On First-Line Egfr Tkis

J. Ma,S. H. Tan,D. Yin, A. Tran,D. Tan,M. Ang,A. Takano, K. H. T. Lim,R. Kanesvaran,A. Jain, T. Rajasekaran,E. Tan,

Journal of Thoracic Oncology（2021）

引用0浏览0引用

Updated Survival And Secondary Safety And Efficacy Analyses From Ca 209-678: A Phase Ii Open-Label Single-Centre Study Of Y90-Radioembolisation (Y90) In Combination With Nivolumab In Asian Patients (Pts) With Advanced Hepatocellular Carcinoma (Ahcc)

J. J. X. Lee,S. H. Tan, T. P. Hennedige, K. S. H. Loke, A. Gogna, D. C. E. Ng, S. Leong,S. Y. Lee, A. K. T. Tong, W. Y. Tham, W. Xie, K. D. Zhuang,

ANNALS OF ONCOLOGY（2021）

引用3浏览0引用

MA04.06 Clinical Characteristics and Outcomes in Advanced KRAS Mutant NSCLC – A Multi-Centre Collaboration in Asia (ATORG-005)

J. Lee,A. Tan,S. Zhou,S. Liu,D. Kim,K. Masuda,U. Batra,H. Hayashi,Y. Goto,S.H. Tan,Y. Wu,D. Tan,

Journal of Thoracic Oncology（2021）

引用0浏览0引用

Randomised Phase 2 Study Of Nivolumab (N) Versus Nivolumab And Ipilimumab (Ni) Combination In Egfr Mutant Nsclc

G. Lai,J. Alvarez,J. C. Yeo,N. L. Sim,A. Tan,S. Zhou,L. Suteja,T. W. Lim,N. Rohatgi,J. Yeong,A. Takano,K. H. T. Lim,

JOURNAL OF THORACIC ONCOLOGY（2021）

引用3浏览0引用

P76.88 Real-World Data of Osimertinib in Patients with Metastatic EGFRm+ NSCLC who Progressed on First-Line EGFR TKIs

J. Ma,S.H. Tan, D. Yin, A. Tran,D. Tan, M. Ang, A. Takano, K.H.T. Lim, R. Kanesvaran, A. Jain, T. Rajasekaran, E. Tan,

Journal of Thoracic Oncologyno. 3 (2021): S627-S628

引用0浏览0引用

Clinical Characteristics And Outcomes In Advanced Kras Mutant Nsclc - A Multi-Centre Collaboration In Asia (Atorg-005)

J. Lee,A. Tan,S. Zhou,S. Liu,D. Kim,K. Masuda,U. Batra,H. Hayashi,Y. Goto,S. H. Tan,Y. Wu,D. Tan,

JOURNAL OF THORACIC ONCOLOGY（2021）

引用0浏览0引用

Outcomes Of Egfr-Mutant Nsclc Patients With De Novo Brain Metastases By Upfront Treatment

J. Ma,Y. Li, G. G. Y. Lai,E-H. Tan, W. D. T. Lim,M-K. Ang,Q. S. Ng,R. Kanesvaran,A. Jain, T. Rajasekaran, K. W. Fong,T. R. Siow,

ANNALS OF ONCOLOGY（2021）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn